Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events

BACKGROUND: Sotrovimab neutralizing SARS-CoV-2 remained effective at the advent of B.1 lineage of the Omicron variant in outpatients. Primarily for hospitalized patients, however, the Japanese government regulated to administer this antibody agent. As this regulation enabled close monitoring in inpa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Junichi, Shiraishi, Kenichiro, Tanaka, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719203/
https://www.ncbi.nlm.nih.gov/pubmed/36461006
http://dx.doi.org/10.1186/s12879-022-07889-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719203/
https://www.ncbi.nlm.nih.gov/pubmed/36461006
http://dx.doi.org/10.1186/s12879-022-07889-z

Ejemplares similares